76 filings
8-K
CRNX
Crinetics Pharmaceuticals Inc
4 Apr 24
Departure of Directors or Certain Officers
4:52pm
8-K
CRNX
Crinetics Pharmaceuticals Inc
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
8-K
CRNX
Crinetics Pharmaceuticals Inc
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
8-K
CRNX
Crinetics Pharmaceuticals Inc
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
8-K
CRNX
Crinetics Pharmaceuticals Inc
28 Feb 24
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:09pm
8-K
3s4616tafe 1g
8 Jan 24
Regulation FD Disclosure
8:03am
8-K
kt3 yl5js5oi0hh
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
vnmj 6t5b1o
12 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:35pm
8-K
lqi3d9p7
7 Nov 23
Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:04pm
8-K
epyt2lbs
13 Sep 23
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
5:23pm
8-K
gj8c0lr
11 Sep 23
Regulation FD Disclosure
6:05am
8-K
pnthh 0cr0dw
8 Aug 23
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:01am
8-K
4uk9y
21 Jun 23
Submission of Matters to a Vote of Security Holders
4:36pm
8-K
ac7icen4wwkwp5j
4 May 23
Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:25pm
8-K
4yhgen1puatgnn1iyuno
13 Mar 23
Other Events
8:30am
8-K
551cm
28 Feb 23
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
4:13pm
8-K
fiz8s1pu
9 Jan 23
Regulation FD Disclosure
8:43am
8-K
08iilc1 3v
28 Nov 22
Crinetics Pharmaceuticals Provides Update on CRN04777 Program
8:32am
8-K
z7j x1z4s9w87
14 Nov 22
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:15am
8-K
2e6 e5z8x
13 Oct 22
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
8:32am